Share 
Bonus TL;DR
- Kalshi recently launched new prediction markets that allow users to wager on FDA drug approval timelines and the outcomes of clinical trials.
- Bioethicist Jonathon Kimmelman warned that these markets pose significant insider trading risks and could create “information cascades,” where market price action improperly distorts public perception of drug research.
Kalshi’s expansion into drug-related prediction markets is drawing ethics scrutiny after bioethicist Jonathon Kimmelman, PhD, warned that contracts tied to FDA approvals and clinical trial outcomes could amplify insider betting risks and distort how the public interprets drug development news.
The concerns were detailed in a September 22, 2026 article from _The American Journal of Managed Care_, which examined Kalshi’s new markets covering cancer and multispecialty drugs. The issue matters beyond healthcare because Kalshi is the first prediction market platform regulated by the Commodity Futures Trading Commission, making its product expansion relevant to the broader U.S. event-contract market.
New Kalshi contracts extend into FDA and trial milestones
According to AJMC, Kalshi announced the new contracts in July 2026. The markets let users bet on FDA approval decisions and also cover the progression and outcomes of phase 1 through 3 clinical trials.
AJMC reported that, at the time of its review, Kalshi listed more contracts on when an FDA approval would happen than on whether a drug would be approved at all. The outlet also found only 1 recorded contract for a clinical trial outcome.
That mix is notable because it suggests the early market was focused more heavily on approval timing than on binary approval outcomes, though AJMC said the full consequences of the contracts may become clearer as the market grows.
Bioethicist warns of herd behavior and insider risks
Kimmelman, a professor of biomedical ethics and associate member of the Department of Experimental Medicine at McGill University, told AJMC that one of his biggest concerns is insider betting, despite safeguards Kalshi says it has in place.
He also warned that prediction markets can produce information cascades that shape judgments around drug news in unhealthy ways.
> “When you’re making judgments based on what other people are saying, that can lead to information cascades, the equivalent of what people sometimes call bubbles, where people engage in herd behavior, and that can lead to really, really inaccurate judgments and distortions,” Kimmelman said.
He added that prediction markets may push participants to follow price action instead of making independent judgments based on evidence.
What to watch next
For prediction market watchers, the next questions are practical as much as ethical: whether Kalshi expands the number of drug-related contracts, what anti-insider safeguards it details publicly, and whether regulators offer any guidance on healthcare-linked event contracts.
AJMC’s reporting stops short of alleging wrongdoing. But it frames a new issue for the U.S. prediction market sector as operators move into more sensitive categories, including products tied to regulatory decisions and clinical research outcomes.
—
Source: As reported by Sabrina McCrear.
